Foundayo: A Rising Competitor in Weight Loss Pills

In its second week on the market, Eli Lilly’s (LLY.N) obesity medication Foundayo garnered 3,707 prescriptions, demonstrating robust early momentum while still lagging behind Novo Nordisk’s rival oral treatment.

These prescription figures indicate that investors might witness substantial revenue generation from the oral weight-management sector as rivalry heats up between these pharmaceutical powerhouses.

Key Takeaways

Foundayo prescriptions jumped to 3,707 in second week launch
Still trails Novo’s oral Wegovy initial performance significantly
Early data shows modest but growing market traction

Market Reaction & Context

Following the prescription data disclosure, Lilly’s stock climbed 2.6%, closing Friday’s trading session above its 200-day moving average ¹. This stock movement stands in contrast to Novo Nordisk (NVO), which declined 1% as market participants assessed competitive pressures in the oral obesity pharmaceutical space.

The week-two numbers mark a substantial advancement from Foundayo’s inaugural week of 1,390 prescriptions ². In comparison, Novo’s oral Wegovy achieved 3,071 prescriptions within its initial four-day period following its January launch, underscoring the competitive hurdles confronting Lilly’s market entry.

Prescription Momentum Analysis

RBC Capital Markets analyst Trung Huynh observed critical distinctions when evaluating the early launch metrics. Foundayo potentially had merely two days of market presence during its initial week, whereas Wegovy enjoyed five complete days ³.

“This implies a more robust launch for Foundayo, with total prescriptions likely building momentum across the subsequent three days of the first week,” Huynh said in a research report ⁴. He expects weeks eight through 12 to provide better indicators of true commercial momentum.

Competitive Landscape & Titration Challenges

Evercore ISI analyst Umer Raffat emphasized possible obstacles regarding patient adherence and dosage progression. Approximately 50% fewer prescriptions are present for the 9-milligram Wegovy tablet than anticipated according to standard titration protocols ⁵.

These oral GLP-1 medications necessitate progressive dosage increases over time to reduce gastrointestinal adverse effects. Foundayo’s briefer 24-hour bodily presence compared to Wegovy’s five-day duration might introduce additional adherence challenges should patients miss doses.

Market Outlook & Analyst Expectations

Financial analysts on Wall Street forecast that oral Wegovy might produce roughly $1.4 billion in revenue this year, establishing a performance standard for Foundayo’s prospects ⁶. RBC’s Huynh anticipates Foundayo reaching 90,000-plus weekly prescriptions by mid-June to maintain alignment with consensus projections.

Jefferies analyst Akash Tewari described Foundayo’s early prescription volumes as “excellent,” while warning that initial weekly data might not reflect the complete scope of pharmacy collaborations ⁷. Lilly had previously indicated that early metrics should be “best interpreted over time rather than as a complete count.”

Strategic Implications

The oral obesity medication sector constitutes a vital growth avenue as both pharmaceutical companies aim to expand accessibility beyond their proven injectable treatments. Lilly’s Zepbound and Novo’s injectable Wegovy presently lead the weight-management drug sector but encounter supply limitations and patient preference obstacles.

Foundayo obtained FDA clearance on April 1st and became accessible via LillyDirect immediately, with expanded retail pharmacy distribution commencing April 9th ⁸. This medication provides once-daily administration without dietary restrictions, potentially attracting patients who prioritize convenience over injectable options.

Not investment advice. For informational purposes only.